Immunosuppressants - Global Market Trajectory & Analytics

Global Immunosuppressants Market to Reach $44.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Immunosuppressants estimated at US$18.2 Billion in the year 2020, is projected to reach a revised size of US$44.1 Billion by 2027, growing at a CAGR of 13.5% over the analysis period 2020-2027. Calcineurin Inhibitors, one of the segments analyzed in the report, is projected to record a 15.5% CAGR and reach US$18.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Corticosteroids segment is readjusted to a revised 13.8% CAGR for the next 7-year period.





The U.S. Market is Estimated at $4.9 Billion, While China is Forecast to Grow at 17.7% CAGR

The Immunosuppressants market in the U.S. is estimated at US$4.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.1 Billion by the year 2027 trailing a CAGR of 17.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.4% and 11.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Monoclonal Antibodies (mAbs) Segment to Record 10.2% CAGR

In the global Monoclonal Antibodies (mAbs) segment, USA, Canada, Japan, China and Europe will drive the 9.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2.4 Billion in the year 2020 will reach a projected size of US$4.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.6 Billion by the year 2027, while Latin America will expand at a 11.6% CAGR through the analysis period.

Select Competitors (Total 43 Featured):

• Astellas Pharma, Inc.
• Bristol Myers Squibb
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc.
• Intas Pharmaceuticals Ltd.
• Johnson & Johnson
• Mylan Laboratories Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi S.A
• Zydus;